View Item 

Show simple item record

Combination Therapy With Adapalene Gel 0.1% and Doxycycline for Severe Acne Vulgaris: A Multicenter, Investigator-Blind, Randomized, Controlled Study
dc.contributor.authorThiboutot, Diane M.en_US
dc.contributor.authorAlan R. , Shalitaen_US
dc.contributor.authorYamauchi, Paul S.en_US
dc.contributor.authorCatherine, Dawsonen_US
dc.contributor.authorStéphanie, Arsonnauden_US
dc.contributor.authorSewon, Kangen_US
dc.date.accessioned2010-06-01T20:41:10Z
dc.date.available2010-06-01T20:41:10Z
dc.date.issued2005-05en_US
dc.identifier.citationDiane M . , Thiboutot; Alan R . , Shalita; Paul S . , Yamauchi; Catherine, Dawson; StÉphanie, Arsonnaud; Sewon, Kang (2005). "Combination Therapy With Adapalene Gel 0.1% and Doxycycline for Severe Acne Vulgaris: A Multicenter, Investigator-Blind, Randomized, Controlled Study." SKINmed: Dermatology for the Clinician 4(3): 138-146. <http://hdl.handle.net/2027.42/73790>en_US
dc.identifier.issn1540-9740en_US
dc.identifier.issn1751-7125en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73790
dc.format.extent975259 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacq Ltd.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2005 Le Jacq Ltd.en_US
dc.titleCombination Therapy With Adapalene Gel 0.1% and Doxycycline for Severe Acne Vulgaris: A Multicenter, Investigator-Blind, Randomized, Controlled Studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherFrom The Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA;en_US
dc.contributor.affiliationotherSUNY Downstate Medical Center, Brooklyn, NY;en_US
dc.contributor.affiliationotherUCLA School of Medicine, Santa Monica, CA;en_US
dc.contributor.affiliationotherGalderma Research & Development, Princeton, NJ;en_US
dc.identifier.pmid15891249en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73790/1/j.1540-9740.2005.04279.x.pdf
dc.identifier.doi10.1111/j.1540-9740.2005.04279.xen_US
dc.identifier.sourceSKINmed: Dermatology for the Clinicianen_US
dc.identifier.citedreferencePawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol. 2004; 14: 4 – 12.en_US
dc.identifier.citedreferenceLeyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003; 49: S200 – S210.en_US
dc.identifier.citedreferenceLayton AM. Psychosocial aspects of acne vulgaris. J Cutan Med Surg. 1998; 2: 19 – 23.en_US
dc.identifier.citedreferenceGollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003; 49: S1 – S37.en_US
dc.identifier.citedreferenceKorting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res. 1989; 15: 447 – 451.en_US
dc.identifier.citedreferenceRietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol. 1983; 22: 41 – 43.en_US
dc.identifier.citedreferenceMills OH Jr, Kligman Kligman Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol. 1978; 58: 555 – 557.en_US
dc.identifier.citedreferenceGollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998; 196: 119 – 125.en_US
dc.identifier.citedreferenceBrogden RN, Goa KL. Adapalene: a review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997; 53: 511 – 519.en_US
dc.identifier.citedreferenceMichel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br J Dermatol 1998; 139 ( suppl 52 ): 3 – 7.en_US
dc.identifier.citedreferenceVega B, Jomard A, Michel S. Regulation of human monocyte toll-like receptor 2 (TLR2) expression by adapalene [abstract]. J Eur Acad Dermatol Venereol. 2002; 16: 123 – 124.en_US
dc.identifier.citedreferenceShroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997; 36: S96 – S103.en_US
dc.identifier.citedreferenceCunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998; 139: 48 – 56.en_US
dc.identifier.citedreferenceWaugh J, Noble S, Scott LJ Adapalene: a review of its use in the treatment of acne vulgaris Drugs. 2004; 64: 1465 – 1478.en_US
dc.identifier.citedreferenceDosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene cream and gel, 0.1% compared to tazarotene cream, 0.05% and 0.1%. Cutis. In press.en_US
dc.identifier.citedreferenceGreenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis. 2003; 72: 76 – 81.en_US
dc.identifier.citedreferenceDunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol. 1998; 139: 17 – 22.en_US
dc.identifier.citedreferenceCaron D, Sorba V, Kerrouche N, et al. Split-face comparison of adapalene 0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol. 1997; 36: S110 – S112.en_US
dc.identifier.citedreferenceEgan N, Loesche MC, Baker MM. Randomized, controlled, bilateral (split-face) comparison trial of the tolerability and patient preference of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001; 68 ( suppl 4 ): 20 – 24.en_US
dc.identifier.citedreferenceBrand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003; 49 ( 3 suppl ): S227 – S232.en_US
dc.identifier.citedreferenceCaron D, Sorba V, Clucas A, et al. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol. 1997; 36: S113 – S115.en_US
dc.identifier.citedreferenceWolf JE Jr, Kaplan Kaplan, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003; 49: S211 – S217.en_US
dc.identifier.citedreferenceCunliffe WJ, Meynadier J, Alirezai M, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol. 2003; 49 ( 3 suppl ): S218 – S226.en_US
dc.identifier.citedreferenceThiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000; 9: 179 – 187.en_US
dc.identifier.citedreferenceHaider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004; 292: 726 – 735.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1540-9740.2005.04279.x.pdf
Size:
952.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.